Oramed CEO to Present at New York Biotechnology Association and The Israel Conference's Fast & Cool™ Session
JERUSALEM, May 28, 2013 /PRNewswire/ --
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that the company's CEO, Nadav Kidron, has been invited to be a speaker at two key events in New York and Los Angeles.
On Wednesday, May 29th, Oramed will be featured at New York Biotechnology Association's 22nd Annual Meeting at the Marriott Marquis Hotel in New York City. Mr. Kidron will discuss the latest developments at Oramed regarding its oral insulin technology.
On Friday, May 31st, in Los Angeles, Mr. Kidron will be part of a panel at The Israel Conference's Fast & Cool™ track featuring Medical Wonders.
NYBA is the leading advocate for advancing the success of the life science industry in New York State and is its main representative to state policy makers, the media, and other communities. NYBA's mission is to support the development and growth of New York's life science industry, and serve its members and the life science community by providing a network for information exchange, shared services and collective action. NYBA's membership comprises bioscience companies, world-class research institutions and related professional services.
For more information: http://www.nyba.org
About The Israel Conference™
The Israel Conference™ spans two days and features leaders of significant businesses that were founded in Israel, have R&D in Israel or do business in Israel. Speakers represent the spirit of the inventiveness of the Israeli market. The diverse cross-section of innovation and design from Israel provides the attendees with an insider's understanding of the growth of both public and privately held Israel-based companies as well as a front-row seat to the technologies and products of tomorrow.
For more information: http://www.theisraelconference.org/
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently initiating Phase 2 clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem.
For more information, the content of which is not part of this press release, please visit http://www.oramed.com
Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss revolutionizing the treatment of diabetes and our oral insulin and oral exenatide candidates approaching Phase 2 clinical trials under U.S. IND and Phase 2a clinical trials, respectively. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.
SOURCE Oramed Pharmaceuticals Inc.